Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
ASCEND trial
Description:
A phase 3 clinical trial evaluating pirfenidone treatment for idiopathic pulmonary fibrosis.
Primary topic:
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (23%)
Related topics:
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (23%),
Antiplatelet Therapy and Cardiovascular Diseases (20%),
Multiple Sclerosis Research Studies (9%),
Chronic Lymphocytic Leukemia Research (8%)
OpenAlex ID:
keywords/ascend-trial
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus
2018
·
The ASCEND Study Collaborative Group
·
New England Journal of Medicine
·
1,279
PDF
Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials
2015
·
Paul W. Noble
, Carlo Albera
, et al.
·
European Respiratory Journal
·
503
PDF
Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis
2016
·
Steven D Nathan
, Carlo Albera
, et al.
·
The Lancet Respiratory Medicine
·
370
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension
2018
·
Raju Kapoor
, Pei-Ran Ho
, et al.
·
The Lancet Neurology
·
359
PDF
Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis
2021
·
Michael Kreuter
, Joyce S. Lee
, et al.
·
American Journal of Respiratory and Critical Care Medicine
·
230
Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis
2017
·
Brett Ley
, Jeffrey Swigris
, et al.
·
American Journal of Respiratory and Critical Care Medicine
·
221
Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis
2016
·
Steven D Nathan
, Carlo Albera
, et al.
·
Thorax
·
187
PDF
Role of aspirin in primary prevention of cardiovascular disease
2019
·
Carlo Patrono
, Colin Baigent
·
Nature Reviews Cardiology
·
172
PDF
An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP)
2017
·
Ulrich Costabel
, Carlo Albera
, et al.
·
Respiration
·
161
PDF
Pirfenidone: A Review of Its Use in Idiopathic Pulmonary Fibrosis
2015
·
Esther S. Kim
, Gillian M. Keating
·
Drugs
·
125
Acalabrutinib Versus Investigator’s Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results
2022
·
Paolo Ghia
, Andrzej Pluta
, et al.
·
HemaSphere
·
123
Predicting Life Expectancy for Pirfenidone in Idiopathic Pulmonary Fibrosis
2017
·
Mark Fisher
, Steven D. Nathan
, et al.
·
Journal of Managed Care & Specialty Pharmacy
·
119
PDF
Prevalence of Aspirin Use for Primary Prevention of Cardiovascular Disease in the United States: Results From the 2017 National Health Interview Survey
2019
·
Colin W. O'Brien
, Stephen P. Juraschek
, et al.
·
Annals of Internal Medicine
·
102
E-cigarettes versus NRT for smoking reduction or cessation in people with mental illness: secondary analysis of data from the ASCEND trial
2015
·
Brigid O’Brien
, Oliver Knight-West
, et al.
·
Tobacco Induced Diseases
·
98
PDF
Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing - ASCEND I and II combined analysis
2011
·
G. R. Lichtenstein
, D. Ramsey
, et al.
·
Alimentary Pharmacology & Therapeutics
·
98
PDF
Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis
2016
·
Michael Kreuter
, Francesco Bonella
, et al.
·
Thorax
·
95
PDF
Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment
2019
·
Steven D. Nathan
, Ulrich Costabel
, et al.
·
Respiratory Medicine
·
86
PDF
Recent Clinical Trials Shed New Light on the Cardiovascular Benefits of Omega-3 Fatty Acids
2019
·
Penny M. Kris-Etherton
, Chesney K. Richter
, et al.
·
Methodist DeBakey Cardiovascular Journal
·
69
Randomised clinical trial: delayed-release oral mesalazine 4.8g/day vs. 2.4g/day in endoscopic mucosal healing - ASCEND I and II combined analysis
2011
·
M.F. Picco
·
Yearbook of Gastroenterology
·
64
Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis
2015
·
Arata Azuma
, Minoru Inomata
, et al.
·
Core evidence
·
57
PDF
Cost-effective recruitment methods for a large randomised trial in people with diabetes: A Study of Cardiovascular Events iN Diabetes (ASCEND)
2016
·
ASCEND Study Collaborative Group
, Theingi Aung
, et al.
·
Trials
·
56
PDF
Serum Neurofilament Light and Multiple Sclerosis Progression Independent of Acute Inflammation
2022
·
Arie R. Gafson
, Xiaotong Jiang
, et al.
·
JAMA Network Open
·
52
PDF
Reliability of Outcome Measures in Clinical Trials in Secondary Progressive Multiple Sclerosis
2020
·
Marcus W. Koch
, Jop Mostert
, et al.
·
Neurology
·
51
Sensitivity and discriminatory ability of the Ankylosing Spondylitis Disease Activity Score in patients treated with etanercept or sulphasalazine in the ASCEND trial
2012
·
D. van der Heijde
, J. Braun
, et al.
·
Rheumatology
·
51
Chronic lesion activity and disability progression in secondary progressive multiple sclerosis
2022
·
Vanessa Beynon
, Ilena C George
, et al.
·
BMJ Neurology Open
·
49
PDF
Show more works
View as search
Works count:
307
Citation count:
6,228
Year
Topic
Type